HIFU

Study examines prostate cancer treatment decisions

5-year study examines common prostate cancer treatment options (See new HIFU study results at bottom of this article.) A five-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care. The CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation for Localized Prostate Cancer) study, coordinated by Vanderbilt University Medical Center, is a multi-site research study conducting long-term followup on men who were diagnosed with localized prostate cancer between 2011 and 2012. The five-year results published in JAMA, with lead author Karen Hoffman, MD, MPH, from MD Anderson, provide evidence on outcomes with [...]

2020-02-18T10:25:52-08:00February 18th, 2020|

HIFU for prostate cancer shows excellent results in new study

Kia Michel, MD The 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer in Washington, D.C. featured Dr. Kia Michel, of Beverly Hills, Calif., who spoke on the outstanding data on focal HIFU outcomes for localized prostate cancer. Dr. Michel presented a poster on near-term HIFU outcomes based on his experience treating men with localized prostate cancer with the Sonablate. He presented that 78 men with prostate cancer underwent HIFU and were tracked post-treatment and re-biopsied at 12 months. He concluded that there was excellent disease control after HIFU ablation and most men were able to retain full urinary continence and erectile function levels equal to those pre-HIFU treatment. “I feel like it is important to report on [...]

2020-02-10T14:04:05-08:00February 10th, 2020|

Study reveals that being active has significant impact on prostate cancer risk

Prostate cancer is the number one cancer risk for men, as well as the No. 2 cancer killer behind lung cancer in the US, yet we still don't know all of its causes. The largest ever study to use genetics as a measurement for physical activity to look at its effect on prostate cancer, reveals that being more active reduces the risk of prostate cancer. Over 140,000 men were included in the study, of which, 80,000 had prostate cancer. This new study, published in the International Journal of Epidemiology in December, was led by the University of Bristol and co-funded by World Cancer Research Fund (WCRF) and Cancer Research UK (CRUK). It found that people with the variation in their DNA sequence that [...]

2020-02-04T13:01:18-08:00February 4th, 2020|

Understanding Prostate Screening & Treatment Options

For some types of cancer, screening can help find cancers at an early stage, when they are more likely to be easier to treat. According to the American Cancer Society, prostate cancer can often be found before symptoms arise by testing the amount of prostate-specific antigen (PSA) in a man’s blood. Another way to find prostate cancer is the digital rectal exam (DRE), in which the doctor puts a gloved, lubricated finger into the rectum to feel the prostate gland. If the results of either one of these tests are abnormal, further testing is often done to see if a man has cancer. If prostate cancer is found as a result of screening with the PSA test or DRE, it will probably be at [...]

2019-12-03T10:47:39-08:00December 3rd, 2019|

Higher omega-3 levels does not increase prostate cancer risk

Omega-3 shown to protect against heart disease-related death, without increasing prostate cancer risk ---> Should you take omega-3 pills? Or try to have two to servings of omega-3 rich fish a week, as the American Heart Association recommends? It may seem a bit murky if you follow headlines about nutrition and health. That's why researchers at the Intermountain Healthcare Heart Institute continue to research the potential benefits and risks of this popular supplement, especially when it comes to prostate cancer risk and heart health. In one study, the Intermountain research team identified 87 patients who were part of the Intermountain INSPIRE Registry and had developed prostate cancer. These patients were also tested for plasma levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid [...]

2019-11-26T09:28:00-08:00November 19th, 2019|

A Typical HIFU Procedure Day

Wake up, get ready, and head to the treatment facility. Patients will need to complete their bowel prep per their MD’s instruction. This is comparable to a prostate biopsy bowel prep. 6 am – 7 am | Arrive at treatment facility, be greeted by staff, and enter procedure preparation area. Patients will typically be asked to arrive at the treatment facility at least an hour before the procedure. 7 am – 10 am | Sonablate HIFU Procedure A typical HIFU procedure lasts between 2-4 hours (depending on the size of the prostate) and is either done under general anesthesia or an epidural and IV sedation. During the procedure a catheter will be put in place to help with urination, and will stay in [...]

2019-11-19T09:50:33-08:00November 12th, 2019|

Researchers identify new factors that may help reduce prostate cancer risk

Men with higher levels of 'free' testosterone and a growth hormone in their blood are more likely to be diagnosed with prostate cancer, according to research presented at the 2019 NCRI Cancer Conference. Other factors such as older age, ethnicity and a family history of the disease are already known to increase a man's risk of developing prostate cancer. However, the new study of more than 200,000 men is one of the first to show strong evidence of two factors that could possibly be modified to reduce prostate cancer risk. The research was led by Dr Ruth Travis, an Associate Professor, and Ellie Watts, a Research Fellow, both based at the Nuffield Department of Population Health, University of Oxford, UK. Dr Travis said: [...]

2019-11-05T08:21:24-08:00November 5th, 2019|

Urine test could offer early detection of prostate cancer

A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection. Currently, the prostate specific antigen (PSA) exam is used as the standard screening method for prostate cancer. However, elevated PSA levels are not exclusive to prostate cancer, as they can also be caused by benign prostate conditions. As a result, an elevated PSA test can sometimes lead to an unnecessary prostate biopsy for the patient, which carries [...]

2019-10-08T10:17:47-07:00October 8th, 2019|

Researchers aim for a paradigm shift in prostate cancer diagnosis

In combination with the current prostate specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment. Prostate cancer is the most common cancer in Western men, with 1.3 million new cases being diagnosed each year worldwide. It is currently detected using a blood test that measures PSA levels. Although it provides early diagnosis, the PSA blood test has a low specificity (high false positives) with about 75 per cent of all PSA positive results ending up with negative biopsies that do not find cancer. When a high PSA level in the blood is detected, the patient undergoes a tissue biopsy of the prostate gland, which is invasive and carries a significant risk of bleeding and [...]

2019-11-26T10:05:32-08:00September 24th, 2019|

Prostate cancer risks may be lowered by mushroom consumption

A new study published in the International Journal of Cancer found an inverse relationship between mushroom consumption and the development of prostate cancer among middle-aged and elderly Japanese men, suggesting that regular mushroom intake might help to prevent prostate cancer. A total of 36,499 men, aged 40 to 79 years who participated in the Miyagi Cohort Study in 1990 and in the Ohsaki Cohort Study in 1994 were followed for a median of 13.2 years. During follow-up, 3.3% of participants developed prostate cancer. Compared with mushroom consumption of less than once per week, consumption once or twice a week was associated with an 8% lower risk of prostate cancer and consumption three or more times per week was associated with a 17% lower [...]

2019-09-17T10:01:10-07:00September 17th, 2019|